Adjuvant therapy in Stage i carcinoma of the breast

The influence of multigene analyses and molecular phenotyping

Gordon F. Schwartz, Harry Bartelink, Harold J. Burstein, Blake Cady, Luigi Cataliotti, Ian S. Fentiman, Roland Holland, Kevin S. Hughes, Shahla Masood, Beryl McCormick, Juan A. Palazzo, Peter I. Pressman, Jorge Reis-Filho, Lajos Pusztai, Emiel J T Rutgers, Andrew D. Seidman, Lawrence J. Solin, Joseph A. Sparano

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

Original languageEnglish (US)
Pages (from-to)303-311
Number of pages9
JournalBreast Journal
Volume18
Issue number4
DOIs
StatePublished - Jul 2012

Fingerprint

Breast Neoplasms
Neoplasm Genes
Consensus
Decision Making
Therapeutics
Steroids
Hormones
Guidelines
Morbidity
Neoplasms

Keywords

  • adjuvant therapy
  • breast carcinoma
  • estrogen receptors
  • gene analysis
  • Her-2-neu
  • Ki-67
  • progesterone receptors

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology
  • Surgery

Cite this

Adjuvant therapy in Stage i carcinoma of the breast : The influence of multigene analyses and molecular phenotyping. / Schwartz, Gordon F.; Bartelink, Harry; Burstein, Harold J.; Cady, Blake; Cataliotti, Luigi; Fentiman, Ian S.; Holland, Roland; Hughes, Kevin S.; Masood, Shahla; McCormick, Beryl; Palazzo, Juan A.; Pressman, Peter I.; Reis-Filho, Jorge; Pusztai, Lajos; Rutgers, Emiel J T; Seidman, Andrew D.; Solin, Lawrence J.; Sparano, Joseph A.

In: Breast Journal, Vol. 18, No. 4, 07.2012, p. 303-311.

Research output: Contribution to journalArticle

Schwartz, GF, Bartelink, H, Burstein, HJ, Cady, B, Cataliotti, L, Fentiman, IS, Holland, R, Hughes, KS, Masood, S, McCormick, B, Palazzo, JA, Pressman, PI, Reis-Filho, J, Pusztai, L, Rutgers, EJT, Seidman, AD, Solin, LJ & Sparano, JA 2012, 'Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping', Breast Journal, vol. 18, no. 4, pp. 303-311. https://doi.org/10.1111/j.1524-4741.2012.01264.x
Schwartz, Gordon F. ; Bartelink, Harry ; Burstein, Harold J. ; Cady, Blake ; Cataliotti, Luigi ; Fentiman, Ian S. ; Holland, Roland ; Hughes, Kevin S. ; Masood, Shahla ; McCormick, Beryl ; Palazzo, Juan A. ; Pressman, Peter I. ; Reis-Filho, Jorge ; Pusztai, Lajos ; Rutgers, Emiel J T ; Seidman, Andrew D. ; Solin, Lawrence J. ; Sparano, Joseph A. / Adjuvant therapy in Stage i carcinoma of the breast : The influence of multigene analyses and molecular phenotyping. In: Breast Journal. 2012 ; Vol. 18, No. 4. pp. 303-311.
@article{434da6044a4141de9253724a73140866,
title = "Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping",
abstract = "A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.",
keywords = "adjuvant therapy, breast carcinoma, estrogen receptors, gene analysis, Her-2-neu, Ki-67, progesterone receptors",
author = "Schwartz, {Gordon F.} and Harry Bartelink and Burstein, {Harold J.} and Blake Cady and Luigi Cataliotti and Fentiman, {Ian S.} and Roland Holland and Hughes, {Kevin S.} and Shahla Masood and Beryl McCormick and Palazzo, {Juan A.} and Pressman, {Peter I.} and Jorge Reis-Filho and Lajos Pusztai and Rutgers, {Emiel J T} and Seidman, {Andrew D.} and Solin, {Lawrence J.} and Sparano, {Joseph A.}",
year = "2012",
month = "7",
doi = "10.1111/j.1524-4741.2012.01264.x",
language = "English (US)",
volume = "18",
pages = "303--311",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Adjuvant therapy in Stage i carcinoma of the breast

T2 - The influence of multigene analyses and molecular phenotyping

AU - Schwartz, Gordon F.

AU - Bartelink, Harry

AU - Burstein, Harold J.

AU - Cady, Blake

AU - Cataliotti, Luigi

AU - Fentiman, Ian S.

AU - Holland, Roland

AU - Hughes, Kevin S.

AU - Masood, Shahla

AU - McCormick, Beryl

AU - Palazzo, Juan A.

AU - Pressman, Peter I.

AU - Reis-Filho, Jorge

AU - Pusztai, Lajos

AU - Rutgers, Emiel J T

AU - Seidman, Andrew D.

AU - Solin, Lawrence J.

AU - Sparano, Joseph A.

PY - 2012/7

Y1 - 2012/7

N2 - A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

AB - A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

KW - adjuvant therapy

KW - breast carcinoma

KW - estrogen receptors

KW - gene analysis

KW - Her-2-neu

KW - Ki-67

KW - progesterone receptors

UR - http://www.scopus.com/inward/record.url?scp=84863646635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863646635&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4741.2012.01264.x

DO - 10.1111/j.1524-4741.2012.01264.x

M3 - Article

VL - 18

SP - 303

EP - 311

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 4

ER -